T he primary pathological hallmarks of Alzheimer's disease are extracellular plaques and intracellular neurofibrillary tangles (NFTs) 1 . The main component of plaques is the amyloid-β (Aβ ) peptide, while NFTs are composed mainly of the protein tau. Autopsy and recent positron emission tomography studies revealed that the formation of plaques is spatially and temporally separated from that of NFTs: plaques first form in the neocortex and spread inward to deeper brain regions, while NFTs first form in limbic areas, from where they spread outward to the neocortex [2] [3] [4] . Several lines of evidence suggest that the propagation of tau pathology into the Aβ plaque-bearing cortex is linked to the transition from the preclinical (asymptomatic) to the clinical (symptomatic) stage of Alzheimer's disease [5] [6] [7] . While previous studies have shown that the interaction between Aβ and tau causes enhanced pathology [6] [7] [8] [9] [10] [11] [12] [13] [14] , the functional consequences for intact neuronal circuits remain unknown. To address this question, we employed in vivo two-photon Ca 2+ imaging of large populations of neurons in layer 2/3 of the neocortex in novel Alzheimer's disease model mice that display spatially overlapping Aβ and tau pathologies in the cortex, similar to Alzheimer's disease patients.
T he primary pathological hallmarks of Alzheimer's disease are extracellular plaques and intracellular neurofibrillary tangles (NFTs) 1 . The main component of plaques is the amyloid-β (Aβ ) peptide, while NFTs are composed mainly of the protein tau. Autopsy and recent positron emission tomography studies revealed that the formation of plaques is spatially and temporally separated from that of NFTs: plaques first form in the neocortex and spread inward to deeper brain regions, while NFTs first form in limbic areas, from where they spread outward to the neocortex [2] [3] [4] . Several lines of evidence suggest that the propagation of tau pathology into the Aβ plaque-bearing cortex is linked to the transition from the preclinical (asymptomatic) to the clinical (symptomatic) stage of Alzheimer's disease [5] [6] [7] . While previous studies have shown that the interaction between Aβ and tau causes enhanced pathology [6] [7] [8] [9] [10] [11] [12] [13] [14] , the functional consequences for intact neuronal circuits remain unknown. To address this question, we employed in vivo two-photon Ca 2+ imaging of large populations of neurons in layer 2/3 of the neocortex in novel Alzheimer's disease model mice that display spatially overlapping Aβ and tau pathologies in the cortex, similar to Alzheimer's disease patients.
Results
Aβ promotes neuronal hyperactivity while tau suppresses activity. We began by monitoring action potential-related spontaneous Ca 2+ transients 15, 16 in GCaMP6f-expressing cortical layer 2/3 neurons of APPswe:PS1Δ E9 (henceforth APP/PS1) transgenic mice that overexpress human Aβ and develop only Aβ plaques, but no cytosolic tau pathology. APP/PS1 mice and all other mice used in this study are on the same FVBB6F1 genetic background (see Methods and Life Sciences Reporting Summary for details regarding the breeding strategy). In agreement with previous results [17] [18] [19] [20] , we detected hyperactivity of layer 2/3 neurons in 6-12-month-old plaque-bearing APP/PS1 mice (mean age 8.4 months; see also Supplementary Figs. 1 and 2a for details regarding age distributions and the rationale for pooling functional neuronal data from mice at this 6-12-month age range) when compared to their wild-type controls (mean age 8.4 months; Fig. 1a-h ). We then analyzed layer 2/3 neuronal activity in agematched rTg4510 transgenic mice that express aggregating human tau P301L and display NFTs but no Aβ pathology (Fig. 1c) . In stark contrast to the results obtained with APP/PS1 mice, in all nine rTg4510 mice (mean age 8.4 months) examined, there was a strong reduction of cortical activity levels ( Fig. 1c-h ; linear mixed effects model (LMEM) for log rates on genetic background, F(2,4351) = 132, P = 1.2 × 10 −56
; all post hoc comparisons between genotypes (controls, APP/PS1, rTg4510) were highly significant, P < 10
−6
). Detailed analysis of all recorded neurons revealed that, relative to controls and APP/PS1 mice, there was a 3.6-fold and 5.8-fold increase in the proportion of silent neurons in the rTg4510 mice (Fig. 1i ), but virtually no neuronal hyperactivity (Fig. 1h) . We then analyzed immunohistochemically stained brain sections from the imaged rTg4510 mice and found that NFTs were present only in 1.21% of GCaMP6f-expressing cells (18 out of 1,483 cells were double-positive for Alz50/ Paired-helical filament 1 (PHF1) and green fluorescent protein (GFP); Supplementary Fig. 3 ), leading us to the hypothesis that tau aggregation is not necessary for neuronal silencing.
To test this hypothesis directly, we performed recordings in rTg21221 mice that overproduce non-aggregating wild-type human tau at comparable levels as rTg4510 mice but lack NFTs (Fig. 2a , right panel, and Supplementary Figs. 4 and 5). Indeed, Fig. 2b -e shows that, similar to rTg4510 mice ( Fig. 1) , in 6-12-month-old rTg21221 mice (n = 6; mean age 8.9 months) there was a marked reduction of layer 2/3 neuronal activity levels (LMEM for log rates on genetic background, F(2,4494) = 183, P = 1.6 × 10 −77
; post hoc multiple comparisons between genotypes were P < 0.0001), as well (Fig. 2e) . These results indicate that the impairment of neurons can occur independently of tau aggregation and NFT formation.
Combination of Aβ and tau leads to suppressed activity. Having demonstrated that Aβ and tau alone have markedly opposite effects on the activity status of neurons, we next asked what is the net effect of Aβ and tau together. To address this question, we performed recordings in 6-12-month-old APP/PS1 mice crossed with rTg4510 or rTg21221 mice 11, 21 ( Fig. 3a-c and Supplementary Fig. 6 ). To our surprise, neuronal hyperactivity was not only completely abolished in the resulting APP/PS1-rTg4510 (n = 8; mean age 7.6 months) and **** **** **** . All post hoc multiple comparisons between genotypes were highly significant: P = 5.42 × 10 −9 for controls vs. APP/ PS1, P = 1.38 × 10 −6 for controls vs. rTg4510, and P = . Post hoc multiple comparisons were P = 2.02 × 10 −8 for controls vs. rTg4510 and P = 1.08 × 10 −8 for APP/PS1 vs. rTg4510 and not significant, P = 0.3972, for controls vs.s APP/PS1. Each solid circle represents an individual animal (controls, n = 7; APP/PS1, n = 5; rTg4510, n = 9) and all error bars reflect the mean ± s.e.m; the differences between genotypes were assessed by one-way ANOVA followed by Tukey's multiple comparisons test, ****P < 0.0001. NS, not significant.
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NATure NeuroSCieNCe APP/PS1-rTg21221 (n = 5; mean age 7.9 months) mice, but there was also a strong reduction in cortical activity levels ( Fig. 3d-j ; LMEM for log rates on genetic background, F(3,5558) = 671, P = 0; post hoc multiple comparisons between genotypes were all P < 2 × 10
−20
). Further analysis revealed that, similar to rTg4510 and rTg21221 mice, abnormally silent neurons constitute a large pool of layer 2/3 neurons both in APP/PS1-rTg4510 and APP/PS1-rTg21221 mice (Fig. 3k) . We independently obtained similar results in a 17-24-month-old cohort of mice (mean age 20.6 months; Supplementary Fig. 7 ; see also Supplementary Figs. 2b and 8 for more details on age distributions and the rationale for pooling neuronal data from mice at this 17-24-month age range).
Given that the rTg4510 transgene is associated with an agedependent loss of neurons, which is enhanced in the APP/ PS1-rTg4510 crosses 11 , potentially contributing to the observed functional impairments, we next analyzed young, 3-4-month-old rTg4510 mice with and without the APP/PS1 transgene. This analysis revealed a strong reduction in neuronal activities (significant effect of group: F(3,5594) = 14.9, P = 1.1 × 10
; post hoc analysis revealed significant differences between the APP/PS1-rTg4510 and all other groups) and increased fractions of silent layer 2/3 neurons in the APP/PS1-rTg4510 crosses already at this early disease stage, before overt neuropathology and neurodegeneration ( Supplementary Fig. 9 ). Supplementary Fig. 10 shows a comparison of the age-dependent changes of cortical neuronal activities for all genotypes. Together, these results indicate that tau blocks Aβ -dependent hyperactivity, resulting in a profound silencing of circuits when both Aβ and tau are present together in the cortex, . All post hoc multiple comparisons between genotypes were significant: P = 5.55 × 10 −8 for controls vs. rTg4510, P = 7.85 × 10 −5 for controls vs. rTg21221, P = 0.0179 for rTg4510 vs. rTg21221. The data for the controls and rTg4510 mice are the same as in Fig. 1 . Each solid circle represents an individual animal and all error bars reflect the mean ± s.e.m; the differences between genotypes were assessed by one-way ANOVA followed by Tukey's multiple comparisons test, *P < 0.05, **P < 0.01, ****P < 0.0001.
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NATure NeuroSCieNCe and they reinforce the idea that NFTs are not critical for this suppression of neuronal activity.
In the presence of Aβ, tau reduction is less effective in rescuing neuronal impairments. Finally, we employed repeated two-photon Ca 2+ imaging and determined, in the same mice, whether impaired neuronal circuit function could be rescued by suppressing tau transgene expression. In these experiments, we took advantage of the fact that the tau mice used in this study were equipped with a regulatable promoter system, which allowed us to turn off the expression of the tau transgene by administering a doxycycline (DOX)-containing diet, as demonstrated in several previous studies [22] [23] [24] . We carried out two-photon Ca 2+ imaging of layer 2/3 neurons in the same mice before and six weeks after DOX treatment (all mice were at least six months of age when DOX treatment was started). We found that the neuronal impairments were apparently completely reversed in rTg21221 (n = 8) and rTg4510 (n = 7) mice ( Fig. 4a-e ; Supplementary Fig. 11 ), despite the continued presence of cortical NFTs ( Supplementary Fig. 12a-c) . However, instead of the expected rescue of circuit impairment, in all five recorded APP/PS1-rTg4510 and all five recorded APP/PS1-rTg21221 mice there was no apparent change in the fractions of silent neurons after DOX treatment ( Fig. 4b-h ; Supplementary Fig. 11 ). The activity levels ( Fig. 4c,d ,f,g) showed a significant interaction between crossing with APP/PS1 and DOX treatment for both rTg4510 and rTg21221 mice (LMEM for log rates on APP/PS1 crossing and DOX treatment, rTg4510:
; post hoc, DOX treatment increased significantly (P < 0.05) the activity level for both crossed and uncrossed strains, but the increase in activity levels for the crossed strain was significantly smaller-compare with ; post hoc, DOX treatment significantly increased activity levels in the uncrossed, but not in the crossed, strain-compare with Fig. 4d,g ). Importantly, the observation that tau suppression in the presence of Aβ was significantly less effective in restoring normal neuronal activities could not be explained by the degree of tau reduction, because enzyme-linked immunosorbent assay (ELISA) analysis showed significant and comparable reductions of total human tau levels on DOX treatment in all genotypes ( Supplementary Fig. 12d-g ). In line with previous reports 22 , we also found that sarkosyl-soluble tau levels, measured in forebrain homogenates of rTg4510 mice with and without the APP/ PS1 transgene using western blot, were reduced by DOX treatment, while sarkosyl-insoluble fractions were not significantly affected ( Supplementary Fig. 13 ).
To determine if tau suppression would be effective in mice harboring tau and Aβ at an earlier age, before substantial neuropathology and neurodegeneration, we treated 3-4-month-old rTg4510 mice with and without the APP/PS1 transgene with DOX for six weeks. Supplementary Fig. 14 shows that, while there was a significant reduction in the fractions of silent neurons in rTg4510 mice (significant effect of treatment, F(1,1388) = 28.1,
), in APP/PS1-rTg4510 crosses the fractions of silent neurons remained unchanged (no significant effect of treatment, F(1,3195) = 0.47, P = 0.49). To show that the effects differed in the rTg4510 mice with and without the APP/PS1 transgene, we performed a LMEM. As expected, there were main effects of APP/PS1 crossing (F(1,4583) = 37.1, P = 1.2 × 10 ); importantly, the interaction was significant (F(1,4583) = 21.9, P = 2.9 × 10 −6
), demonstrating that the difference between the effects of DOX treatment in the young rTg4510 and APP/PS1-rTg4510 mice were highly significant. Again, ELISA analysis showed a substantial reduction in total human tau levels in all mice receiving DOX ( Supplementary Fig. 14e,f) . As a control, we treated wild-type control mice with DOX and found no significant effects (Supplementary Fig. 15; F(1,2686) = 0.589, P = 0.44).
Discussion
Our study reveals that the two major proteins involved in Alzheimer's disease have dramatically opposing effects on the activity of neuronal circuits in vivo. Aβ alone causes hyperactivity, whereas tau alone suppresses activity and promotes silencing of many neurons. Remarkably, neuronal silencing dominates over hyperactivity when Aβ and tau are present together, which is corroborated by a recent in vitro study employing extracellular field recordings in entorhinal cortex slices 25 . However, the dramatic dominance of tau was unexpected in light of previous studies suggesting that tau regulates, and is essential for, Aβ -dependent hyperexcitability [26] [27] [28] . While the effects of transgene insertion must always be considered, the Aβ -induced hyperactivity phenotype is observed in multiple amyloid precursor protein (APP)-overexpressing lines with different transgene arrays 29 and is blocked by β -site amyloid precursor protein cleaving enzyme (BACE) inhibitors, which presumably impact primarily Aβ generation 20 ; the tau phenotype is observed in two different tau transgenic lines that express two different tau transgenes (tau P301L or wild-type) with substantially different age-related histopathological phenotypes (aggregated tau and NFTs and neurodegeneration in rTg4510, or not in the rTg21221 line). Taken together with the observation that DOX suppression of the transgene ameliorates the abnormal physiology, we believe that the most parsimonious explanation for these observations is that Aβ and tau are responsible for the hyperactivity and suppressed baseline excitability observed in our study.
Our results fit well with and provide a possible cellular explanation for the clinical observations that (1) Alzheimer's disease . Post hoc multiple comparisons were highly significant: P = 2.02 × 10 −9 for APP/PS1 vs. APP/PS1-rTg4510 as well as APP/PS1 vs. APP/PS1-rTg21221 (P = 1.21 × 10 . All post hoc multiple comparisons between genotypes were significant: P = 5.72 × 10 −9 for APP/PS1 vs. APP/PS1-rTg4510; P = 4.87 × 10 −6 for APP/PS1 vs. APP/PS1-rTg21221; and P = 0.002 for APP/PS1-rTg4510 vs. APP/PS1-rTg21221. Data for APP/PS1 mice are the same as shown in Fig. 1 . Each solid circle represents an individual animal and all error bars reflect the mean ± s.e.m; the differences among genotypes were assessed by one-way ANOVA followed by Tukey's multiple comparisons test, *P < 0.05, **P < 0.01, ****P < 0.0001. NS, not significant.
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NATure NeuroSCieNCe patients exhibit a progressive decrease of whole-brain activity [30] [31] [32] and regional cerebral blood flow 33 as well as a slowing of the electroencephalogram 34 , and that (2) tau, rather than Aβ , determines cognitive status 7, 35, 36 . The dominance of tau could also explain the relative lack of clinical improvement after Aβ suppression in recent clinical trials. In this context, it is noteworthy that Alzheimer's disease carries an increased risk of epileptic seizures 37 , and that several studies have shown increased activation of brain regions, such as the hippocampus, using blood oxygenation level-dependent functional magnetic resonance imaging 38, 39 (but see Khan et al. 40 ). To reconcile these observations with our results, it is important to better understand the precise relationship between single-neuron and (abnormal) population activity. Nonetheless, as neuronal hyperactivity appears to be more related to Aβ 29 , it is possible that epileptiform Frequency (transients per min)
A P P / P S 1 A P P / P S 1 -r T g 4 5 1 0 A P P / P S 1 -r T g 2 1 2 2 1 A P P / P S 1 A P P / P S 1 -r T g 4 5 1 0 A P P / P S 1 -r T g 2 1 2 2 1 A P P / P S 1 A P P / P S 1 -r T g 4 5 1 0 A P P / P S 1 -r T g lobe. This appears to be the case for hyperactivity in the hippocampus diagnosed with functional magnetic resonance imaging 38 . Our finding that tau suppresses neuronal activity agrees with previous electrophysiological studies [41] [42] [43] and goes on to demonstrate that soluble, non-aggregated tau is sufficient for neuronal silencing, and Silent neurons before and after tau suppression A P P / P S 1 -r T g 4 5 1 0 b a s e l i n e A P P / P S 1 -r T g 2 1 2 2 1 b a s e l i n e A P P / P S 1 -r T g 4 5 1 0 a f t e r t a u s u p p r e s s i o n A P P / P S 1 -r T g 2 1 2 2 1 a f t e r t a u s u p p r e s s i o n ; rTg21221 before DOX, 40.45 ± 3.68% vs. after DOX, 15.87 ± 1.74%, t = 6.047, d.f. = 9.972, P = 1.26 × 10
−4
). f, Frequency distributions from APP/PS1-rTg4510 mice before (n = 1,262 neurons in 5 mice) and after (n = 827 neurons in same 5 mice) DOX. g, The same is shown for APP/PS1-rTg21221 mice (before DOX, n = 795 neurons in 5 mice; after DOX, n = 904 neurons in the same 5 mice). h, Fractions of silent neurons in APP/ PS1-rTg4510 (left; n = 5 mice) and APP/PS1-rTg21221 (right; n = 5 mice) before and after DOX. APP/PS1-rTg4510 before DOX, 64.25 ± 4.21% vs. after DOX, 61.87 ± 2.28%, t = 0.4962, d.f. = 6.152, P = 0.6370. APP/PS1-rTg21221 before DOX, 44.72 ± 4.59% versus after DOX, 46.04 ± 2.64%, t = 0.2494, d.f. = 6.387, P = 0.8109. Each solid circle represents an individual animal and the error bars represent the mean ± s.e.m.; the differences among groups were assessed using two-sided Welch's t tests, ***P < 0.001. NS, not significant.
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NATure NeuroSCieNCe that NFTs are not required. The link between soluble tau and neuronal dysfunction may provide a mechanistic explanation for the observation that, in mouse models, cognitive deficits occur independently of NFT formation 22, [44] [45] [46] [47] [48] ; that NFTs are not necessarily associated with functional impairments is also in line with previous studies showing that NFT-bearing cortical neurons can reliably respond to strong synaptic inputs, for example, during simple sensory stimuli 49, 50 . Another unexpected but intriguing result of our study was the finding that suppression of tau gene expression rescued neuronal circuit impairments in tau mice, but was significantly less effective when Aβ was present at the same time. This lack of effect was present already in young mice, before substantial neuropathology, synapse loss, and neurodegeneration; nonetheless, it may be related to more severe and persisting synaptic and cellular changes in the context of (soluble) Aβ -tau interactions compared to Aβ or tau alone. Notably, aggregated tau in NFTs is the target for several ongoing clinical trials; our current data argue that readouts for these trials also need to be reconsidered. Together, our results clarify the pathological role of interaction between Aβ and tau in impairing neuronal circuit integrity and function in Alzheimer's disease, with important mechanistic and therapeutic implications not only for Alzheimer's disease, but also for other tauopathies and conditions that are associated with elevated tau.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41593-018-0289-8.
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NATure NeuroSCieNCe Methods Animals. The generation, care, and use of animals as well as all experimental procedures were approved by the Institutional Animal Care and Use Committees of the Massachusetts General Hospital and McLaughlin Research Institute for Biomedical Sciences. All mice were housed in standard mouse cages on wood bedding under conventional laboratory conditions (12-h dark and 12-h light cycle, constant temperature and humidity); they were given food and water ad libitum. Male and female mice were used in the study and randomly allocated to the experiments. B6.Cg-Tg(APPswe, PSEN1dE9)85Dbo/MmJ mice (henceforth designated APP/PS1) were initially obtained from The Jackson Laboratory 51 . APP/PS1 mice were crossed with the B6.Cg-Tg(Camk2a-tTA)1/Mmay tet transactivator strain that expresses tetracycline-controlled transactivator protein (tTA) from the CK-tTA transgene exclusively in the forebrain 52 . Double transgenic B6.CK-tTA, APP/PS1 males were selected as sires for the experimental cross with dams from the tetracycline-responsive element strain FVBTg(tetO-MAPT*P301L)4510/Kha/Jlws (henceforth Tg4510) or FVB-Tg(tetO-MAPT*wt)21221 (henceforth Tg21221) to produce APP/PS1-rTg4510 or APP/PS1-rTg21221 mice with the experimental, tau-expressing genotypes plus mice negative for either the responder or transactivator transgene that do not express any human tau. All of the same sex offspring of these crosses share the FVBB6F1 background and are genetically identical to one another except for the transgene arrays that they carry.
Surgery and injection of genetically encoded Ca
2+ indicator. Mice were initially anesthetized with 4% isoflurane in O 2 and maintained on 2% isoflurane during the surgical procedure. The body temperature of the anesthetized mice was maintained at ~37.5 °C using a heating pad; ophthalmic ointment was applied to protect the eyes. Using aseptic techniques, the skin above the skull was removed and, by using a fine-tipped dental drill, two craniotomies were performed over the left and right parietal cortices. Then, the fast and ultrasensitive genetically encoded fluorescent Ca 2+ sensor GCaMP6f 16 (AAV1.Syn.GCaMP6f.WPRE.SV40; purchased from University of Pennsylvania Vector Core), was stereotactically (Kopf Instruments) injected into layer 2/3 (∼ 300 μ m deep) at a rate of 0.2 µ l min −1 using a Pump 11 Elite microsyringe pump (Harvard Apparatus). A single injection (~1 µ l of viral construct) was made in each cortical hemisphere. A round glass coverslip (8 mm diameter) was placed over both craniotomies and sealed to the bone using a mix of dental cement and cyanoacrylate 50 . After surgery, mice were returned to their home cage for 2-3 weeks. Analgesia (buprenorphine and acetaminophen) was continued for 3 d postoperatively.
In vivo two-photon fluorescence microscopy. To minimize brain statedependent experimental variables 53 and for better comparison with previous studies [17] [18] [19] [20] , in the present study imaging was performed under light isoflurane anesthesia. Mice were anesthetized with 4% isoflurane in O 2 for induction; a reduced concentration of isoflurane (~1%) was used during the imaging. After induction, we waited at least 60 min before imaging. The animal's body temperature was maintained at ~37.5 °C with a heating pad; ophthalmic ointment was applied to protect the eyes. Two-photon imaging was performed on a Fluoview FV1000MPE multiphoton microscope (Olympus) equipped with a mode-locked MaiTai Ti:sapphire laser (Spectra-Physics) tuned to 900 nm. Spontaneous Ca 2+ fluorescence signals from cortical layer 2/3 were recorded at ~15 Hz through a 25× , 1.05 numerical aperture water immersion objective (6× digital zoom; Olympus). Scanning and image acquisition was controlled by the Fluoview software (Olympus). Imaging was carried out across multiple fields of view (256 × 256 pixels, 84.41 × 84.41 µ m) per mouse, and each field of view was recorded for at least 130 s. Image analysis was performed offline using the Fiji package of ImageJ (National Institutes of Health) and Igor Pro (WaveMetrics). First, regions of interest were drawn around individual neuronal somata; then, relative GCaMP6f fluorescence change versus time traces were generated for each region of interest. Ca 2+ transients were identified as changes in relative fluorescence that were three times larger than the s.d. of the baseline fluorescence. Based on previous protocols 19, 20 , neurons were classified according to their individual activity rates as silent (0 transients per min), normal (0-6 transients per min), or hyperactive (≥ 6 transients per min).
Immunohistochemistry. Brain hemispheres from mice were drop fixed in 4% paraformaldehyde in PBS for 48 h at 4 °C. After fixation, brains were washed with PBS, cryoprotected with 30% sucrose, and sliced into 40-µ m-thick coronal sections with a sliding microtome (SM2000 R; Leica). Sections were rinsed three times in Tris-buffered saline (TBS) and then permeabilized with 0.2% Triton X-100 in TBS for 20 min. Sections were then blocked in 10% normal goat serum (NGS) in TBS for 60 min at room temperature, followed by overnight incubation at 4 °C in primary antibodies diluted in 5% NGS. The following primary antibodies were used: mouse anti-Alz50 immunoglobulin M (IgM, 1:500, courtesy of Peter Davies); chicken anti-GFP (1:1,000; Aves Labs); rabbit anti-human Aβ (1:500; IBL America); mouse anti-PHF1 IgG (1:1,000, courtesy of Peter Davies). After three washes in TBS, sections were incubated in secondary antibodies diluted in 5% NGS for 60 min at room temperature. After three washes in TBS, sections were incubated in secondary antibodies diluted in 5% NGS for 60 min at room temperature. The following secondary antibodies were used: goat anti-mouse IgM, μ chain, Cy3 conjugate (1:1,000; EMD Millipore); Alexa Fluor 488 goat anti-chicken (1:1,000; Invitrogen); Alexa Fluor 647 goat anti-rabbit (1:500; Invitrogen); Alexa Fluor 647 goat anti-mouse IgG (1:500; Invitrogen). After three washes in TBS, sections were mounted on microscope slides in 4,6-diamidino-2-phenylindole (DAPI) VECTASHIELD Antifade Mounting Medium (Vector Laboratories) and coverslipped. Images were recorded on a Axio Imager microscope (ZEISS) equipped with a CoolSNAP digital camera (Photometrics) and AxioVision software version 4.8. Stereological quantifications of NFTs and amyloid plaques were performed using the Computer Assisted Stereological Toolbox (Olympus). All counting was conducted blinded to genotype and treatment. Further information about the antibodies used for immunohistochemistry can be found in the Life Sciences Reporting Summary.
Tau protein analysis. Mouse forebrain was homogenized with a dounce homogenizer in 300 µ l PBS with protease inhibitor (100:1, Thermo Fisher Scientific) and spun at 10,000g for 10 min at 4 °C. The pellet was collected for sarkosyl extraction. Protein concentration was determined with a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). ELISA was performed using the Phospho(Thr231)/Total Tau Kit (MSD), following the manufacturer's protocol. All samples were run in duplicate and fitted to an eight-point standard curve to determine concentration. To isolate sarkosyl-soluble/insoluble tau, the same protein quantity of mouse brain lysate pellet was resuspended in cold TBS and centrifuged at 150,000g for 15 min at 4 °C. The pellet was then homogenized in 3× salt/sucrose buffer (0.8 M NaCl, 10% sucrose, 10 mN Tris base, pH 7.4) and centrifuged at 150,000g for 15 min at 4 °C. The supernatant was collected, adjusted to 1% sarkosyl and incubated for 1 h at 37 °C. Samples were then centrifuged at 150,000g for 30 min at 4 °C. The supernatant and pellets were collected. Pellets were resuspended with radioimmunoprecipitation assay buffer containing 1% SDS and sonicated for 20 min in a Branson 2510 sonicator. Both supernatant (sarkosyl-soluble) and pellets (sarkosyl-insoluble) were then analyzed by western blot as follows: sarkosyl-soluble and insoluble fractions were mixed with 1× final lithium dodecyl sulfate sample buffer (Invitrogen) and 50 mM dithiothreitol (10× Sample Reducing Agent; Invitrogen), and boiled for 5 min. Samples were loaded in 4-12% Bis-Tris gel (Invitrogen) and run at 130 V for 90 min in 1× MES SDS Running Buffer (Invitrogen). Proteins were then transferred to an activated polyvinylidene fluoride membrane (EMD Millipore) in 1× transfer buffer (BioRad Laboratories) at 75 V for 75 min. Membranes were then blocked for 1 h using the Odyssey Blocking Buffer (LI-COR Biosciences) at room temperature and then incubated with a mouse anti-human Tau antibody (TAU-13, 1:2,500; BioLegend) and a chicken anti-glyceraldehyde 3-phosphate dehydrogenase antibody (1:5,000; EMD Millipore) in blocking buffer (LI-COR Biosciences) overnight at 4 °C. Membranes were then washed 3 × 10 min in TBS with Tween 20, and then incubated with secondary antibodies (goat anti-mouse IgG IRDye 680RD and donkey anti-chicken IgG IRDye 800CW; both LI-COR Biosciences) for 1 h at room temperature. Membranes were imaged using a LI-COR Biosciences imaging station using the Odyssey software. Blots were converted to gray scale and densitometry analysis was performed in ImageJ. Further information about the antibodies used for tau protein analysis can be found in the Life Sciences Reporting Summary.
Statistics.
No statistical methods were used to predetermine sample sizes; however, our sample sizes are similar to those reported in previous publications (see, for example, Busche et al. 17 , Grienberger et al. 18 , Busche et al. 19 , and Keskin et al. 20 ) . No animals or data points were excluded from the analysis. Biochemical and histological analyses were conducted blinded to genotype and treatment, whereas in vivo microscopy and analysis were not performed blinded to the conditions of the experiments. The distributions of firing rates of neurons were analyzed using LMEMs with animal as a random factor, and fixed factors as stated in the main text. Since the distributions of firing rates were highly skewed to the right, a log transformation was used to ensure normality. This was the best Box-Cox transformation for these data. Firing rates of 0 were coded as half the lowest non-zero observed rate before the log transformation. Computations were performed using the function fitlme in the statistical toolbox of Matlab version R2017b (MathWorks). Statistical comparison between two experimental groups was assessed with a two-sided Welch's t test; differences between multiple groups were assessed using one-way analysis of variance (ANOVA) followed by a Tukey's multiple comparisons test. P < 0.05 was considered statistically significant. Analysis routines and the code used in this study can be requested from the corresponding authors.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
All data are reported in the main text and supplementary materials, stored at the Massachusetts General Hospital, and are available from the corresponding authors upon reasonable request. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data collection
In vivo image aquisition was controlled by the Fluoview Software FV10-ASW (Olympus, ver. 04.02). Immunhistochemical images were collected with a Zeiss Axio-Imager microscope equipped with a Coolsnap digital camera and Axio-Vision V4.8. Stereological quantifications of tau neurofibrillary tangles and amyloid plaques were performed using the Computer Assisted Stereological Toolbox (Olympus). Western blot membranes were imaged using a LI-COR imaging station equipped with the Odyssey software (ver. 3.0). ELISA analysis was performed using the Meso Scale Diagnostics (MSD) Phospho (Thr231)/Total Human Tau ELISA kit (MSD #K15121D).
Data analysis
Analysis of imaging and Western blot data was performed using the Fiji Package of ImageJ (NIH, ver. 2.0.0-rc-59/1.51k), as well as IGOR Pro (Wavemetrics, ver. 6.32). Graphs were generated in GraphPad Prism 7. Statistical analysis was carried out using GraphPad Prism 7 and MATLAB 2017b.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. All studies must disclose on these points even when the disclosure is negative.
Sample size
We aimed for high-quality recordings from a commonly used and statistically sufficient sample size. Sample size was chosen on the basis of pilot experiments, previous experiences with similar types of experiments and was similar to those reported in previous publications (see e.g. refs. [17] [18] [19] [20] . We also found that the variability between individual animals and recordings was low, which indicates that acquisition of additional data would not alter our results.
Data exclusions No data points were excluded from the analysis.
Replication
All findings in this study were collected from multiple independent experiments, and were reliably reproduced.
Randomization For all experiments, mice were selected randomly.
Blinding
For all experiments, the experimenter was aware of the conditions being tested. Importantly, all data analysis was performed using semiautomated routines, developed prior to data acquisition. All biochemical analyses and counting of amyloid plaques and tau tangles was conducted blinded to genotype and treatment.
Reporting for specific materials, systems and methods 4) Rabbit anti-Human Aβ (1:500, IBL America, cat. no. 18584, lot 1E-330, polyclonal), this antibody has been used and validated in several previous studies including Hudry et al., Gene transfer of human APOE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain, Sci. Transl. Med., 2013. 10) Chicken anti-GAPDH antibody (1:5000, EMD Millipore Corp, AB2302, lot 3022890, polyclonal), this antibody has been validated and used in the Hyman laboratory and in multiple previous publications that are listed in the manufacturer's website.
Validation
All antibodies have been validated for the applications used within this manuscript (see above) and for the commercial antibodies this information is available on the manufacturers' publicly accessible datasheets. The tau antibodies Alz50, PHF1 and Tau-13 have been extensively used and validated in the Hyman laboratory (including immunohistochemistry in tg4510 and tau null tissue) and have been published previously in multiple studies by many different laboratories.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals B6.Cg-Tg(APPswe, PSEN1dE9)85Dbo/MmJ mice (hereafter designated APP/PS1) were initially obtained from Jackson Laboratory (Bar Harbor, ME). APP/PS1 mice were crossed to the B6.Cg-Tg(Camk2a-tTA)1/Mmay tet transactivator strain that expresses tTA from the CK-tTA transgene exclusively in the forebrain (see ref. 59). Double transgenic B6.CK-tTA, APP/PS1 males were selected as sires for the experimental cross to dams from the tetracycline-responsive element strain FVB-Tg(tetO-MAPT*P301L)4510/ Kha/Jlws (Tg4510) or FVB-Tg(tetO-MAPT*wt)21221 (Tg21221) to produce APP/PS1-rTg4510 or APP/PS1-rTg21221 mice with the experimental, tau-expressing genotypes plus mice negative for either the responder or transactivator transgene that do not express any human tau. All of the same sex offspring of these crosses share the FVBB6F1 background and are genetically identical to one another except for the transgene arrays that they carry. Both male and female mice were used and three different ages were studied: young (3-to 4-months), adult (6-to 12-months) and aged (17-to 24-months). All animal experiments were approved by the Massachusetts General Hospital's and McLaughlin Research Institute's Institutional Animal Care and Use Committees.
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
